,
5 min read
Clinical Evaluation Reports (CERs) are a central element of conformity assessment under the EU Medical Device Regulation 2017/745. Although Annex XIV establishes the formal requirements for conducting and documenting clinical evaluation, experience from EU MDR audits consistently shows that Annex XIV compliance alone rarely satisfies Notified Body expectations. Increasingly, Notified Bodies focus on whether CER demonstrates defensible, lifecycle-based clinical evidence rather than procedural completeness.
This evolution reflects the regulatory intent of MDR: to ensure that clinical evidence meaningfully supports safety and performance throughout the entire device lifecycle. Understanding Notified Bodies expectations beyond Annex XIV has therefore become essential for manufacturers navigating MDR certification, surveillance audits and MDR transition activities for a medical device.
From Structural Compliance to Evidence Defensibility
Annex XIV provides an essential framework, but does not define the quality, relevance or contextual interpretation of clinical evidence required for a robust CER. As a result, Notified Bodies frequently identify CERs that are technically complete yet fail to justify evidence selection, address limitations or explain the validity of conclusions over time.
This regulatory shift is reflected in Medical Device Coordination Group (MDCG) guidance on clinical evaluation and post-market surveillance, emphasizing that clinical evaluation must be iterative and continuously updated using new clinical and post-market data. Similarly, the European Commission’s MDR implementation resources consistently position clinical evaluation as part of an integrated evidence system rather than a static report.
Consequently, clinical evaluation is increasingly viewed within broader clinical and performance evaluation approaches, where clinical data, risk management and post-market evidence are developed and maintained coherently, consistent with EU MDR clinical evaluation and clinical evidence requirements.
How Notified Bodies Assess Clinical Evaluation Reports
Notified Body reviewers assess how convincingly the CER demonstrates conformity with the General Safety and Performance Requirements (GSPR) and whether the clinical evidence aligns with the device’s intended purpose and risk profile, forming the basis of a Notified Body opinion.
A defensible CER clearly narrates, explains evidence selection, assessment of uncertainties, limitations, and demonstrates how the overall evidence supports safety and performance claims. These expectations align closely with MEDDEV 2.7/1 revision 4, which continues to influence assessments performed by notified body reviewers, despite its origin under the Medical Device Directives (MDD).
This narrative coherence remains fundamental to robust clinical evaluation of medical devices under MDR.
Literature Review as a Core Element of Clinical Evidence
Notified Bodies now demand a high level of rigor for literature reviews, as they are considered a cornerstone for demonstrating clinical performance and safety under the EU MDR. They expect a systematic, reproducible and unbiased search process, with every step from search strategies and databases to inclusion/exclusion criteria and appraisal methods, being transparently documented. A failure to meet these standards or to use literature that is not current or relevant to the clinical questions, is a primary reason for review deficiencies and is one of the most frequent issues cited by reviewers.
These expectations are reinforced internationally in IMDRF guidance on clinical evaluation, which identifies structured literature appraisal as a basis for evidence generation. Well-defined literature review methodologies therefore play a critical role in establishing the credibility of a CER, especially where clinical investigations are limited.
Defining State of the Art (SOTA) Under MDR
State of the art (SOTA) has become a critical element of clinical evaluation with Notified Bodies assessing generic or outdated descriptions, particularly supporting equivalence or performance claims.
A defensible SOTA analysis explains current medical knowledge, technologies, clinical practices and how the subject device compares against accepted benchmarks. Weak or poorly substantiated SOTA often undermine equivalence arguments and raise questions about the clinical relevance.
Article 61 and Demonstrating Sufficient Clinical Evidence
Article 61 of the EU MDR requires manufacturers to demonstrate sufficient clinical evidence for conformity. This is particularly challenging for legacy devices and those relying on equivalence. Notified Bodies expect CERs to clearly justify sufficiency, identify data gaps and address residual uncertainty. Historical market use alone is rarely sufficient; manufacturers must follow a structured, evidence-based approach consistent with MDCG 2020-6 and aligned with EU MDR clinical evaluation and clinical evidence requirements.
Clinical Evaluation Across the Device Lifecycle
A key MDR requirement is that clinical evaluation must stay aligned with post-market evidence throughout the device lifecycle. Notified Bodies routinely check consistency between CER conclusions, PMS data, PSURs and PMCF activities. Inconsistencies often indicate fragmented evidence management. Integrating clinical evaluation within lifecycle management supports traceability and ensures conclusions remain current and defensible, consistent with MDCG 2020-7.
Emerging Expectations for SaMD and AI-Based Devices
Software as a Medical Device (SaMD) and AI-enabled technologies introduce additional complexity into clinical evaluation of medical devices. While MDR principles apply, Notified Bodies place heightened emphasis on clinical performance validation, algorithms transparency and management of iterative updates.
These expectations align with IMDRF guidance on Software as a Medical Device (SaMD) and broader regulatory perspectives from European Medicines Agency (EMA) on digital health and artificial intelligence.
Conclusion: Reframing Clinical Evaluation Under EU MDR
Under the EU MDR, CERs are no longer judged solely on Annex XIV compliance. Notified Bodies expect scientifically rigorous, transparent and continuously maintained clinical evidence that reflects current clinical practice and real-world experience.
Manufacturers that treat clinical evaluation as a one-time exercise often face repeated challenges with evidence sufficiency, relevance and traceability. Those adopting a lifecycle-driven approach based on European Commission, MDCG, MEDDEV, IMDRF and EMA guidance are better equipped to meet notified Body expectations and maintain long-term compliance.
How Freyr Supports Clinical Evaluation Under EU MDR
Navigating EU MDR clinical evaluation demands scientific rigor, methodological consistency and a lifecycle evidence strategy. Freyr supports manufacturers with CER development/remediation, gap assessments, literature-based evaluations and alignment with post-market and risk management processes.
Freyr’s experts collaborate with manufacturers to address Notified Body feedback, strengthen evidence under Article 61 and support complex technologies like SaMD and AI devices. For support with clinical evaluation, CER development or EU MDR clinical evidence strategy, speak to Freyr expert about your regulatory challenges.
